Literature DB >> 18050296

Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort.

Montserrat Aceituno1, Esther García-Planella, Carolina Heredia, Yamile Zabana, Faust Feu, Eugeni Domènech, Miquel Angel Gassull, Julián Panés.   

Abstract

BACKGROUND: One-third of patients with steroid-refractory ulcerative colitis (UC) do not respond to cyclosporine and require colectomy. Since alternative pharmacological treatments for this condition are available, it is pertinent to identify factors that predict response. The objective of this study was to determine predictive factors of response prior to cyclosporine administration, with validation in an independent cohort.
METHODS: The 2 cohorts of patients were identified from prospectively established databases. All patients had received 1 mg/kg/day prednisolone or equivalent for at least 5 days before cyclosporine. The efficacy measure was need of early surgery (within 3 months).
RESULTS: From 1998 to 2005, 34 patients were treated in 1 institution (derivation cohort) and 38 patients in the second institution (validation cohort). Eleven patients in the derivation cohort and 9 patients in the validation cohort underwent early colectomy. Univariate analysis in the derivation cohort demonstrated a significant association of colectomy with C-reactive protein (P = 0.012) and the Ho index before initiation of cyclosporine (P = 0.013). Regression analysis showed that only the Ho index (P = 0.011) had an independent predictive value. The Ho index predicted need of colectomy, with an area under the characteristic receiver operating curve of 0.79 (95% confidence interval [CI], 0.59-0.99) in the derivation cohort and 0.74 (95% CI, 0.53-0.96) in the validation cohort. The cutoff point with the best sensitivity and specificity ratio was > or =5.
CONCLUSIONS: The Ho-based predictive score is a good predictor of response to cyclosporine and avoidance of colectomy, and may aid in the indication of this treatment for management of steroid-resistant UC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18050296     DOI: 10.1002/ibd.20322

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  10 in total

Review 1.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

Review 2.  Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review.

Authors:  Travis Murdoch; Sarah O'Donnell; Mark S Silverberg; Remo Panaccione
Journal:  Can J Gastroenterol Hepatol       Date:  2015-05

Review 3.  Strategies for the care of adults hospitalized for active ulcerative colitis.

Authors:  Suresh Pola; Derek Patel; Sonia Ramamoorthy; Elisabeth McLemore; Marianne Fahmy; Jesus Rivera-Nieves; John T Chang; Elisabeth Evans; Michael Docherty; Mark Talamini; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2012-07-24       Impact factor: 11.382

Review 4.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

5.  Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity.

Authors:  Cosimo Prantera; Stefano Marconi
Journal:  Therap Adv Gastroenterol       Date:  2013-03       Impact factor: 4.409

Review 6.  Optimizing conventional therapy for inflammatory bowel disease.

Authors:  Marc Schwartz; Russell Cohen
Journal:  Curr Gastroenterol Rep       Date:  2008-12

7.  Activation of TGF-β activated kinase 1 promotes colon mucosal pathogenesis in inflammatory bowel disease.

Authors:  Zhiwei Liu; Fansheng Kong; Jefferson E Vallance; Eleana Harmel-Laws; Surya Amarachintha; Kris A Steinbrecher; Michael J Rosen; Sandip Bhattacharyya
Journal:  Physiol Rep       Date:  2017-04

8.  Markers of Systemic Inflammation in Acute Attacks of Ulcerative Colitis: What Level of C-reactive Protein Constitutes Severe Colitis?

Authors:  Anthony Croft; Anton Lord; Graham Radford-Smith
Journal:  J Crohns Colitis       Date:  2022-08-04       Impact factor: 10.020

Review 9.  Current approaches to the management of new-onset ulcerative colitis.

Authors:  Renée Marchioni Beery; Sunanda Kane
Journal:  Clin Exp Gastroenterol       Date:  2014-05-09

10.  The effect of pre-admission immunosuppression on colectomy rates in acute severe ulcerative colitis.

Authors:  Desmond Patrick; James Doecke; James Irwin; Katherine Hanigan; Lisa Simms; Mariko Howlett; Graham Radford-Smith
Journal:  Therap Adv Gastroenterol       Date:  2018-11-13       Impact factor: 4.409

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.